Atezolizumab for urothelial bladder cancer – second and subsequent line

NIHR HSRIC
Record ID 32016000351
English
Authors' objectives: Atezolizumab is intended to be used as second and subsequent line therapy for the treatment of locally advanced or metastatic urothelial bladder cancer. If licensed, it will provide an additional treatment option for this patient group. Atezolizumab is a monoclonal antibody targeting programmed cell death-1 ligand (PD-L1 or CD274 antigen) that acts as an immune check-point inhibitor. Atezolizumab does not currently have Marketing Authorisation in the EU for any indication. Bladder cancer is the seventh most common cancer in the UK, accounting for 3% of new cases. There were 8,858 new diagnoses in England in 2011, equating to an age-standardised incidence rate of 11.1 per 100,000 population. Survival is dependent on the stage of the disease at diagnosis. One-year survival for locally advanced disease is 59% and 38% for men and women respectively; for metastatic disease, one-year survival is 26% and 25% for men and women respectively. Treatment options for urothelial bladder cancer are dependent on the stage of disease, tumour size, and the general health of the patient. Current second line treatment options for locally advanced or metastatic bladder cancer include chemotherapy (including gemcitabine with cisplatin, and carboplatin or gemcitabine with paclitaxel), surgery, and radiotherapy. Atezolizumab is currently in phase III clinical trials comparing its effect on overall survival against treatment with chemotherapy.
Details
Project Status: Completed
Year Published: 2015
URL for published report: http://www.hsric.nihr.ac.uk/topics/atezolizumab-for-urothelial-bladder-cancer-second-and-subsequent-line/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antibodies, Monoclonal, Humanized
  • Carcinoma, Transitional Cell
  • Urinary Bladder Neoplasms
  • Urologic Neoplasms
  • Immune Checkpoint Inhibitors
  • Antineoplastic Agents
Contact
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name: c.packer@bham.ac.uk
Contact Email: c.packer@bham.ac.uk
Copyright: NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.